Abstract
The N-methyl-d-aspartate (NMDA) receptor antagonist ketamine is known to induce various pharmacological effects. It has attracted attention because of its rapid and sustained antidepressant effects in depressed patients, although its side effects have raised some concerns. NMDA receptors are considered to mediate various effects of ketamine, but other systems may be involved. NMDA receptors are di-heteromeric complexes that are composed of two GluN1 subunits and two homomeric GluN2A-D/3A subunits, or tri-heteromeric complexes that are composed of two GluN1 subunits and two heteromeric GluN2A-D/GluN3A, B subunits. The involvement of each NMDA receptor subunit in the neural mechanisms that underlie the various effects of ketamine remains unclear. This chapter focuses on GluN2 subunits and discusses the involvement of each GluN2 subunit in various pharmacological actions of ketamine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, Mizuno N (1994) Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol 347(1):150–160. https://doi.org/10.1002/cne.903470112
Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE Jr, Jones EG (1996) Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16(1):19–30
Anastasio NC, Xia Y, O’Connor ZR, Johnson KM (2009) Differential role of N-methyl-D-aspartate receptor subunits 2A and 2B in mediating phencyclidine-induced perinatal neuronal apoptosis and behavioral deficits. Neuroscience 163(4):1181–1191. https://doi.org/10.1016/j.neuroscience.2009.07.058
Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475(7354):91–95. https://doi.org/10.1038/nature10130
Bartlett TE, Bannister NJ, Collett VJ, Dargan SL, Massey PV, Bortolotto ZA, Fitzjohn SM, Bashir ZI, Collingridge GL, Lodge D (2007) Differential roles of NR2A and NR2B-containing NMDA receptors in LTP and LTD in the CA1 region of two-week old rat hippocampus. Neuropharmacology 52(1):60–70. https://doi.org/10.1016/j.neuropharm.2006.07.013
Belujon P, Grace AA (2014) Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity. Biol Psychiatry 76(12):927–936. https://doi.org/10.1016/j.biopsych.2014.04.014
Beneyto M, Meador-Woodruff JH (2008) Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33(9):2175–2186. https://doi.org/10.1038/sj.npp.1301604
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351–354
Boyce-Rustay JM, Holmes A (2006) Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 31(11):2405–2414. https://doi.org/10.1038/sj.npp.1301039
Brady KT, Balster RL (1982) Discriminative stimulus properties of ketamine stereoisomers in phencyclidine-trained rats. Pharmacol Biochem Behav 17(2):291–295
Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997) Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154(6):805–811. https://doi.org/10.1176/ajp.154.6.805
Brigman JL, Daut RA, Wright T, Gunduz-Cinar O, Graybeal C, Davis MI, Jiang Z, Saksida LM, Jinde S, Pease M, Bussey TJ, Lovinger DM, Nakazawa K, Holmes A (2013) GluN2B in corticostriatal circuits governs choice learning and choice shifting. Nat Neurosci 16(8):1101–1110. https://doi.org/10.1038/nn.3457
Can A, Zanos P, Moaddel R, Kang HJ, Dossou KS, Wainer IW, Cheer JF, Frost DO, Huang XP, Gould TD (2016) Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters. J Pharmacol Exp Ther 359(1):159–170. https://doi.org/10.1124/jpet.116.235838
Chaperon F, Muller W, Auberson YP, Tricklebank MD, Neijt HC (2003) Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit. Behav Pharmacol 14(5-6):477–487. https://doi.org/10.1097/01.fbp.0000091471.79060.ed
Coyle JT, Tsai G, Goff D (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 1003:318–327
de Lima MN, Laranja DC, Bromberg E, Roesler R, Schroder N (2005) Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res 156(1):139–143. https://doi.org/10.1016/j.bbr.2004.05.016
De Vry J, Jentzsch KR (2003) Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. Behav Pharmacol 14(3):229–235. https://doi.org/10.1097/01.fbp.0000069577.37661.ce
Dix S, Gilmour G, Potts S, Smith JW, Tricklebank M (2010) A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists. Psychopharmacology (Berl) 212(2):227–242. https://doi.org/10.1007/s00213-010-1945-1
Domino EF (2010) Taming the ketamine tiger 1965. Anesthesiology 113(3):678–684. https://doi.org/10.1097/ALN.0b013e3181ed09a2
Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, Almonte A, Murray E, Mosely C, Barber J, French A, Balster R, Murray TF, Traynelis SF (2007) Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol 581(Pt 1):107–128. https://doi.org/10.1113/jphysiol.2006.124958
Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, Kirkwood K, Aan Het Rot M, Lapidus KA, Wan LB, Iosifescu D, Charney DS (2014) Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiat 71(6):681–688. https://doi.org/10.1001/jamapsychiatry.2014.62
Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B (2009) Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 33(1):70–75. https://doi.org/10.1016/j.pnpbp.2008.10.005
Franks NP, Lieb WR (1994) Molecular and cellular mechanisms of general anaesthesia. Nature 367(6464):607–614. https://doi.org/10.1038/367607a0
Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K, Chaki S (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361(1):9–16. https://doi.org/10.1124/jpet.116.239228
Garcia LS, Comim CM, Valvassori SS, Reus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32(1):140–144. https://doi.org/10.1016/j.pnpbp.2007.07.027
Gideons ES, Kavalali ET, Monteggia LM (2014) Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A 111(23):8649–8654. https://doi.org/10.1073/pnas.1323920111
Gielen M, Siegler Retchless B, Mony L, Johnson JW, Paoletti P (2009) Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 459(7247):703–707. https://doi.org/10.1038/nature07993
Gupta A, Devi LA, Gomes I (2011) Potentiation of m-opioid receptor-mediated signaling by ketamine. J Neurochem 119(2):294–302. https://doi.org/10.1111/j.1471-4159.2011.07361.x
Gupta SC, Ravikrishnan A, Liu J, Mao Z, Pavuluri R, Hillman BG, Gandhi PJ, Stairs DJ, Li M, Ugale RR, Monaghan DT, Dravid SM (2016) The NMDA receptor GluN2C subunit controls cortical excitatory-inhibitory balance, neuronal oscillations and cognitive function. Sci Rep 6:38321. https://doi.org/10.1038/srep38321
Hagino Y, Kasai S, Han W, Yamamoto H, Nabeshima T, Mishina M, Ikeda K (2010) Essential role of NMDA receptor channel e4 subunit (GluN2D) in the effects of phencyclidine, but not methamphetamine. PLoS One 5(10):e13722. https://doi.org/10.1371/journal.pone.0013722
Han LC, Yao LN, Wu SX, Yang YH, Xu LX, Chai W (2010) The effect of ketamine on N-methyl-D-aspartate receptor subunit expression in neonatal rats. Eur J Anaesthesiol 27(2):181–186. https://doi.org/10.1097/EJA.0b013e328330d453
Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11(10):682–696. https://doi.org/10.1038/nrn2911
Higgins GA, Ballard TM, Enderlin M, Haman M, Kemp JA (2005) Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. Psychopharmacology (Berl) 179(1):85–98. https://doi.org/10.1007/s00213-005-2203-9
Hikosaka O (2010) The habenula: from stress evasion to value-based decision-making. Nat Rev Neurosci 11(7):503–513. https://doi.org/10.1038/nrn2866
Hillman BG, Gupta SC, Stairs DJ, Buonanno A, Dravid SM (2011) Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. Neurobiol Learn Mem 95(4):404–414. https://doi.org/10.1016/j.nlm.2011.01.008
Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27(43):11496–11500. https://doi.org/10.1523/JNEUROSCI.2213-07.2007
Ide S, Ikeda K (2018) Mechanisms of the antidepressant effects of ketamine enantiomers and their metabolites. Biol Psychiatry 84(8):551–552. https://doi.org/10.1016/j.biopsych.2018.07.018
Ide S, Ikekubo Y, Mishina M, Hashimoto K, Ikeda K (2017) Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine. J Pharmacol Sci 135(3):138–140. https://doi.org/10.1016/j.jphs.2017.11.001
Ide S, Ikekubo Y, Mishina M, Hashimoto K, Ikeda K (2019) Cognitive impairment that is induced by (R)-ketamine is abolished in NMDA GluN2D receptor subunit knockout mice. Int J Neuropsychopharmacol 22(7):449–452. https://doi.org/10.1093/ijnp/pyz025
Insel TR, Wang PS (2009) The STAR∗D trial: revealing the need for better treatments. Psychiatr Serv 60(11):1466–1467. https://doi.org/10.1176/appi.ps.60.11.1466
Kantrowitz JT, Javitt DC (2010) N-methyl-D-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 83(3-4):108–121. https://doi.org/10.1016/j.brainresbull.2010.04.006
Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors: implications for models of schizophrenia. Mol Psychiatry 7(8):837–844. https://doi.org/10.1038/sj.mp.4001093
Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23):3095–3105. https://doi.org/10.1001/jama.289.23.3095
Khlestova E, Johnson JW, Krystal JH, Lisman J (2016) The role of GluN2C-containing NMDA receptors in ketamine’s psychotogenic action and in schizophrenia models. J Neurosci 36(44):11151–11157. https://doi.org/10.1523/JNEUROSCI.1203-16.2016
Klepstad P, Maurset A, Moberg ER, Oye I (1990) Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 187(3):513–518
Kocsis B (2012) Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol Psychiatry 71(11):987–995. https://doi.org/10.1016/j.biopsych.2011.10.002
Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73(12):1133–1141. https://doi.org/10.1016/j.biopsych.2013.03.026
Kutsuwada T, Sakimura K, Manabe T, Takayama C, Katakura N, Kushiya E, Natsume R, Watanabe M, Inoue Y, Yagi T, Aizawa S, Arakawa M, Takahashi T, Nakamura Y, Mori H, Mishina M (1996) Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor ε2 subunit mutant mice. Neuron 16(2):333–344
Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329(5994):959–964. https://doi.org/10.1126/science.1190287
Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, Li XY, Aghajanian G, Duman RS (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69(8):754–761. https://doi.org/10.1016/j.biopsych.2010.12.015
Lima-Ojeda JM, Vogt MA, Pfeiffer N, Dormann C, Kohr G, Sprengel R, Gass P, Inta D (2013) Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain. Prog Neuropsychopharmacol Biol Psychiatry 45:28–33. https://doi.org/10.1016/j.pnpbp.2013.04.017
Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63(4):349–352. https://doi.org/10.1016/j.biopsych.2007.05.028
Mallick F, McCullumsmith CB (2016) Ketamine for treatment of suicidal ideation and reduction of risk for suicidal behavior. Curr Psychiatry Rep 18(6):61. https://doi.org/10.1007/s11920-016-0680-7
Martucci L, Wong AH, De Luca V, Likhodi O, Wong GW, King N, Kennedy JL (2006) N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and mRNA levels. Schizophr Res 84(2-3):214–221. https://doi.org/10.1016/j.schres.2006.02.001
McNally JM, McCarley RW, McKenna JT, Yanagawa Y, Brown RE (2011) Complex receptor mediation of acute ketamine application on in vitro gamma oscillations in mouse prefrontal cortex: modeling gamma band oscillation abnormalities in schizophrenia. Neuroscience 199:51–63. https://doi.org/10.1016/j.neuroscience.2011.10.015
Miller OH, Yang L, Wang CC, Hargroder EA, Zhang Y, Delpire E, Hall BJ (2014) GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife 3:e03581. https://doi.org/10.7554/eLife.03581
Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T (2001) Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor ε1 subunit. J Neurosci 21(2):750–757
Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921–2927
Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12(3):529–540
Morgan CJ, Curran HV (2012) Ketamine use: a review. Addiction 107(1):27–38. https://doi.org/10.1111/j.1360-0443.2011.03576.x
Murray TF, Leid ME (1984) Interaction of dextrorotatory opioids with phencyclidine recognition sites in rat brain membranes. Life Sci 34(20):1899–1911
Neske GT, Patrick SL, Connors BW (2015) Contributions of diverse excitatory and inhibitory neurons to recurrent network activity in cerebral cortex. J Neurosci 35(3):1089–1105. https://doi.org/10.1523/JNEUROSCI.2279-14.2015
Nosyreva E, Szabla K, Autry AE, Ryazanov AG, Monteggia LM, Kavalali ET (2013) Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci 33(16):6990–7002. https://doi.org/10.1523/JNEUROSCI.4998-12.2013
Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14(6):383–400. https://doi.org/10.1038/nrn3504
Petrenko AB, Yamakura T, Fujiwara N, Askalany AR, Baba H, Sakimura K (2004) Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-D-aspartate receptor GluRε1 subunit. Anesth Analg 99(4):1136–1140. https://doi.org/10.1213/01.ANE.0000131729.54986.30
Petrenko AB, Yamakura T, Sakimura K, Baba H (2014) Defining the role of NMDA receptors in anesthesia: are we there yet? Eur J Pharmacol 723:29–37. https://doi.org/10.1016/j.ejphar.2013.11.039
Picard N, Takesian AE, Fagiolini M, Hensch TK (2019) NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity. Mol Psychiatry 24(6):828–838. https://doi.org/10.1038/s41380-018-0341-9
Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28(6):631–637. https://doi.org/10.1097/JCP.0b013e31818a6cea
Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66(5):522–526. https://doi.org/10.1016/j.biopsych.2009.04.029
Rampon C, Tang YP, Goodhouse J, Shimizu E, Kyin M, Tsien JZ (2000) Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nat Neurosci 3(3):238–244. https://doi.org/10.1038/72945
Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR (2012) Evaluation of sigma (s) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol 22(4):308–317. https://doi.org/10.1016/j.euroneuro.2011.08.002
Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16(3):675–686
Sapkota K, Mao Z, Synowicki P, Lieber D, Liu M, Ikezu T, Gautam V, Monaghan DT (2016) GluN2D N-methyl-D-aspartate receptor subunit contribution to the stimulation of brain activity and gamma oscillations by ketamine: implications for schizophrenia. J Pharmacol Exp Ther 356(3):702–711. https://doi.org/10.1124/jpet.115.230391
Sato Y, Kobayashi E, Murayama T, Mishina M, Seo N (2005) Effect of N-methyl-D-aspartate receptor ε1 subunit gene disruption of the action of general anesthetic drugs in mice. Anesthesiology 102(3):557–561
Seamans J (2008) Losing inhibition with ketamine. Nat Chem Biol 4(2):91–93. https://doi.org/10.1038/nchembio0208-91
Shi Q, Guo L, Patterson TA, Dial S, Li Q, Sadovova N, Zhang X, Hanig JP, Paule MG, Slikker W Jr, Wang C (2010) Gene expression profiling in the developing rat brain exposed to ketamine. Neuroscience 166(3):852–863. https://doi.org/10.1016/j.neuroscience.2010.01.007
Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, Van Nueten L (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80(6):424–431. https://doi.org/10.1016/j.biopsych.2015.10.018
Sutton MA, Taylor AM, Ito HT, Pham A, Schuman EM (2007) Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis. Neuron 55(4):648–661. https://doi.org/10.1016/j.neuron.2007.07.030
Swanger SA, Vance KM, Pare JF, Sotty F, Fog K, Smith Y, Traynelis SF (2015) NMDA receptors containing the GluN2D subunit control neuronal function in the subthalamic nucleus. J Neurosci 35(48):15971–15983. https://doi.org/10.1523/JNEUROSCI.1702-15.2015
Tozzi A, de Iure A, Bagetta V, Tantucci M, Durante V, Quiroga-Varela A, Costa C, Di Filippo M, Ghiglieri V, Latagliata EC, Wegrzynowicz M, Decressac M, Giampa C, Dalley JW, Xia J, Gardoni F, Mellone M, El-Agnaf OM, Ardah MT, Puglisi-Allegra S, Bjorklund A, Spillantini MG, Picconi B, Calabresi P (2016) Alpha-synuclein produces early behavioral alterations via striatal cholinergic synaptic dysfunction by interacting with GluN2D N-methyl-D-aspartate receptor subunit. Biol Psychiatry 79(5):402–414. https://doi.org/10.1016/j.biopsych.2015.08.013
Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62(3):405–496. https://doi.org/10.1124/pr.109.002451
Watanabe M, Inoue Y, Sakimura K, Mishina M (1992) Developmental changes in distribution of NMDA receptor channel subunit mRNAs. Neuroreport 3(12):1138–1140
Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons DM, Rodriguez CI, Schatzberg AF (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 175(12):1205–1215. https://doi.org/10.1176/appi.ajp.2018.18020138
Winters BD, Bussey TJ (2005) Glutamate receptors in perirhinal cortex mediate encoding, retrieval, and consolidation of object recognition memory. J Neurosci 25(17):4243–4251. https://doi.org/10.1523/JNEUROSCI.0480-05.2005
World Health Organization (2017) The selection and use of essential medicines, 21st edn. World Health Organization, Geneva
Wyllie DJ, Livesey MR, Hardingham GE (2013) Influence of GluN2 subunit identity on NMDA receptor function. Neuropharmacology 74:4–17. https://doi.org/10.1016/j.neuropharm.2013.01.016
Yamamoto H, Kamegaya E, Sawada W, Hasegawa R, Yamamoto T, Hagino Y, Takamatsu Y, Imai K, Koga H, Mishina M, Ikeda K (2013) Involvement of the N-methyl-D-aspartate receptor GluN2D subunit in phencyclidine-induced motor impairment, gene expression, and increased Fos immunoreactivity. Mol Brain 6:56. https://doi.org/10.1186/1756-6606-6-56
Yamamoto T, Nakayama T, Yamaguchi J, Matsuzawa M, Mishina M, Ikeda K, Yamamoto H (2016) Role of the NMDA receptor GluN2D subunit in the expression of ketamine-induced behavioral sensitization and region-specific activation of neuronal nitric oxide synthase. Neurosci Lett 610:48–53. https://doi.org/10.1016/j.neulet.2015.10.049
Yamamoto H, Kamegaya E, Hagino Y, Takamatsu Y, Sawada W, Matsuzawa M, Ide S, Yamamoto T, Mishina M, Ikeda K (2017) Loss of GluN2D subunit results in social recognition deficit, social stress, 5-HT2C receptor dysfunction, and anhedonia in mice. Neuropharmacology 112(Pt A):188–197. https://doi.org/10.1016/j.neuropharm.2016.07.036
Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632. https://doi.org/10.1038/tp.2015.136
Yang C, Han M, Zhang JC, Ren Q, Hashimoto K (2016) Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 239:281–283. https://doi.org/10.1016/j.psychres.2016.03.034
Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, Hu H (2018) Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature 554(7692):317–322. https://doi.org/10.1038/nature25509
Yuan H, Hansen KB, Vance KM, Ogden KK, Traynelis SF (2009) Control of NMDA receptor function by the NR2 subunit amino-terminal domain. J Neurosci 29(39):12045–12058. https://doi.org/10.1523/JNEUROSCI.1365-09.2009
Zanos P, Gould TD (2018) Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 23(4):801–811. https://doi.org/10.1038/mp.2017.255
Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533(7604):481–486. https://doi.org/10.1038/nature17998
Zhang X, Chergui K (2015) Dopamine depletion of the striatum causes a cell-type specific reorganization of GluN2B- and GluN2D-containing NMDA receptors. Neuropharmacology 92:108–115. https://doi.org/10.1016/j.neuropharm.2015.01.007
Zhang C, Li Z, Wu Z, Chen J, Wang Z, Peng D, Hong W, Yuan C, Wang Z, Yu S, Xu Y, Xu L, Xiao Z, Fang Y (2014a) A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. Psychopharmacology (Berl) 231(4):685–693. https://doi.org/10.1007/s00213-013-3297-0
Zhang JC, Li SX, Hashimoto K (2014b) R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav 116:137–141. https://doi.org/10.1016/j.pbb.2013.11.033
Zhang X, Feng ZJ, Chergui K (2014c) Allosteric modulation of GluN2C/GluN2D-containing NMDA receptors bidirectionally modulates dopamine release: implication for Parkinson’s disease. Br J Pharmacol 171(16):3938–3945. https://doi.org/10.1111/bph.12758
Acknowledgment
The authors thank Michael Arends for English editing.
Conflict of Interest: Authors declare no potential conflicts of interest.
Funding: This work was supported by JSPS KAKENHI (16K15565, 16H06276, and 17H04324 to K. I. and 17K08612 to S. I.), MEXT KAKENHI (16H06276 [AdAMS] to K. I.), AMED (JP19dk0307071, JP18mk0101076, and JP19ek0610011 to K. I.), and the Smoking Research Foundation (K. I.).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ide, S., Ikeda, K. (2020). Distinct Roles of NMDA Receptor GluN2 Subunits in the Effects of Ketamine and Its Enantiomers. In: Hashimoto, K., Ide, S., Ikeda, K. (eds) Ketamine. Springer, Singapore. https://doi.org/10.1007/978-981-15-2902-3_10
Download citation
DOI: https://doi.org/10.1007/978-981-15-2902-3_10
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-2901-6
Online ISBN: 978-981-15-2902-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)